Immunome Inc.

Was schiefgehen könnte

1. 1Varegacestat has not received marketing approval; the Food and Drug Administration could reject its application or require more information before a decision.
2. 2Immunome has no product-sale revenue, reports continuing losses, and expects to need additional financing to fund development and potential commercialization.
3. 3Drug development results are uncertain: clinical trials may not show adequate safety or benefit, and early results may not predict later trial outcomes.